DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Hypoxic modification of radiotherapy with nimorazole has previously been shown to increase
radiosensitivity in hypoxic head and neck squamous cell carcinomas (HNSCC).
In Denmark, nimorazole is added the radiotherapy of most HNSCC, as it has not previously been
possible to discriminate more hypoxic tumours from less hypoxic tumours.
A hypoxia gene profile has shown to discriminate between responders and non-responders to
nimorazole.
In DAHANCA 30, expected hypoxia profile guided non-responders are randomized to +/-
nimorazole during radiotherapy.This in order to verify clinical use of the gene profile in
selecting the relevant patients for hypoxic modification of radiotherapy with nimorazole.